We performed a genetic drug target analysis for the 22 genes for which we have evidence of function pointing to the gene in addition to the established MA gene CACNA1A. Drugs at various levels of development target four genes that associate with MA (PRRT2, ABO, LRRK2 and CACNA1A), none associated with MO, and four genes that associate with overall migraine or severe headaches (KCNK5, NGF, SCN11A and TRPM8; Supplementary Table 23 and Supplementary Note 5). This evidence concerns the gene LRRK2 and migraine disorder.